Clinical Trial Update: Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating pembrolizumab with Imprime PGG in metastatic non-small cell lung cancer after progression on first-line therapy; results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Imprime PGG
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Lawrence Feldman, MD | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-08-13